Leerink Partnrs Has Positive Outlook for TNGX Q2 Earnings

Tango Therapeutics, Inc. (NASDAQ:TNGX) – Research analysts at Leerink Partnrs increased their Q2 2025 earnings per share estimates for shares of Tango Therapeutics in a research report issued to clients and investors on Monday, May 12th. Leerink Partnrs analyst A. Berens now expects that the company will post earnings of ($0.29) per share for the quarter, up from their previous forecast of ($0.36). The consensus estimate for Tango Therapeutics’ current full-year earnings is ($1.19) per share. Leerink Partnrs also issued estimates for Tango Therapeutics’ Q3 2025 earnings at ($0.30) EPS, Q4 2025 earnings at ($0.27) EPS, FY2025 earnings at ($1.22) EPS, FY2026 earnings at ($1.11) EPS and FY2027 earnings at ($1.80) EPS.

Tango Therapeutics (NASDAQ:TNGX) last released its quarterly earnings data on Monday, May 12th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.02). Tango Therapeutics had a negative return on equity of 49.64% and a negative net margin of 284.42%. The company had revenue of $5.39 million for the quarter, compared to analyst estimates of $6.73 million.

Separately, HC Wainwright restated a “buy” rating and issued a $13.00 price target on shares of Tango Therapeutics in a research report on Monday, April 14th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $12.33.

Tango Therapeutics Stock Performance

TNGX opened at $1.52 on Thursday. The firm has a market cap of $164.32 million, a price-to-earnings ratio of -1.29 and a beta of 1.02. The firm’s 50-day simple moving average is $1.46 and its 200-day simple moving average is $2.58. Tango Therapeutics has a twelve month low of $1.03 and a twelve month high of $12.02.

Institutional Trading of Tango Therapeutics

Several large investors have recently made changes to their positions in the business. TCG Crossover Management LLC bought a new stake in Tango Therapeutics during the 4th quarter worth about $33,174,000. Boxer Capital Management LLC acquired a new position in shares of Tango Therapeutics during the fourth quarter worth approximately $32,077,000. Gilead Sciences Inc. acquired a new position in shares of Tango Therapeutics during the fourth quarter worth approximately $15,000,000. Farallon Capital Management LLC bought a new stake in shares of Tango Therapeutics during the fourth quarter valued at approximately $12,360,000. Finally, Nantahala Capital Management LLC acquired a new stake in shares of Tango Therapeutics in the fourth quarter valued at approximately $8,666,000. Institutional investors own 78.99% of the company’s stock.

About Tango Therapeutics

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.